Seshiru Nakazawa 研究室

主宰者：Seshiru Nakazawa

群馬大学・Gunma University Hospital

AI 要約（直近 5 年の研究成果）

要約はまだ生成されていません。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（98 件）

[2026] Supplementary Figure 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698221
[2026] Supplementary Table 19 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698095
[2026] Supplementary Figure 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698176
[2026] Supplementary Figure 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698167
[2026] Supplementary Table 8 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698023
[2026] Supplementary Table 6 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698032
[2026] Supplementary Figure S1 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708713
[2026] Supplementary Figure S2 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708710
[2026] Supplementary Table 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698044
[2026] Supplementary Table 25 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698056

続きを表示（残り 88 件）

[2026] Supplementary Table 17 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698101
[2026] Supplementary Table 16 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698104
[2026] Supplementary Figure 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698209
[2026] Supplementary Table 14 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698113
[2026] Supplementary Figure S5 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708698
[2026] Supplementary Figure S4 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708704
[2026] Supplementary Table 1 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698134
[2026] Supplementary Figure 7 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698155
[2026] Supplementary Table 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698125
[2026] Supplementary Table S1 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708695
[2026] Supplementary Figure S3 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708707
[2026] Supplementary Table S3 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708689
[2026] Supplementary Table 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698086
[2026] Supplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698119
[2026] Supplementary Table 4 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698041
[2026] Supplementary Table 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698035
[2026] Supplementary Table 9 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698017
[2026] Supplementary Figure 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698215
[2026] Supplementary Table 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698092
[2026] Supplementary Table 15 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698110
[2026] Supplementary Table 24 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698062
[2026] Supplementary Figure 1 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698227
[2026] Supplementary Figure 16 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698197
[2026] Supplementary Figure 14 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698203
[2026] Supplementary Figure 6 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698161
[2026] Supplementary Figure 15 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698200
[2026] Supplementary Figure 17 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698194
[2026] Supplementary Figure 8 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698149
[2026] Supplementary Figure 18 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698191
[2026] Supplementary Table 21 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698083
[2026] Supplementary Figure 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698206
[2026] Supplementary Figure 9 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698143
[2026] Supplementary Table 26 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698050
[2026] Supplementary Figure 6 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708716
[2026] Supplementary Table 22 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698077
[2026] Supplementary Table 18 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698098
[2026] Supplementary Table 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698128
[2026] Supplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698182
[2026] Supplementary Table 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698131
[2026] Supplementary Table 7 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698029
[2026] Supplementary Figure 4 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698170
[2026] Supplementary Table 23 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698071
[2026] Supplementary Table S2 from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.32708692
[2026] Data from Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.c.8542399
[2026] Supplementary Figure 19 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698188
[2026] Supplementary Figure 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698173
[2026] Lectin‑captured plasma microRNAs predict response and survival in patients with non‑small cell lung cancer treated with nivolumab
DOI: https://doi.org/10.3892/ol.2026.15669
[2026] Right middle and lower bilobectomy using a modified fissureless technique: a case report
DOI: https://doi.org/10.1186/s44215-026-00262-5
[2026] Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2 -Driven Tumors
DOI: https://doi.org/10.1158/1078-0432.ccr-25-4390
[2026] Non-mucinous, enteric-type thymic adenocarcinoma: genetic analysis of a case
DOI: https://doi.org/10.1186/s44215-026-00240-x
[2026] Ectopic Cervical Thymoma with Myasthenia Gravis and Pure Red Cell Aplasia: A Case Report
DOI: https://doi.org/10.70352/scrj.cr.25-0818
[2025] Completion lobectomy following segmentectomy for malignant lung tumors: a multi-institutional study of surgical feasibility, oncologic outcomes, and diagnostic challenges (ESSG-02 study)
DOI: https://doi.org/10.21037/tlcr-2025-1099
[2025] P3.12.63 MTAPloss Is Frequent and Potentially Targetable With PRMT5 Inhibitors in Oncogene-Driven NSCL
DOI: https://doi.org/10.1016/j.jtho.2025.09.925
[2025] Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations
DOI: https://doi.org/10.1016/j.jtho.2025.09.010
[2025] Acceptability of Elderly Donors in Living Kidney Transplantation: Long-Term Outcomes from Donors Aged 70 Years or Older
DOI: https://doi.org/10.1016/j.ajt.2025.07.1603
[2025] Desensitization with Plasma Exchange, High-Dose IVIG, and Rituximab in XM-Positive Kidney Transplantation: ABO-Compatible vs. Incompatible Cases
DOI: https://doi.org/10.1016/j.ajt.2025.07.962
[2025] SMARCB1‐Deficient Pulmonary Mesenchymal Tumor Without Malignant Histological Features
DOI: https://doi.org/10.1111/pin.70025
[2025] Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
DOI: https://doi.org/10.1158/2159-8290.cd-24-1726
[2025] Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
DOI: https://doi.org/10.1016/j.jtho.2025.03.045
[2025] A Rare Case of Sarcomatoid-Type Localized Pleural Mesothelioma Derived From Visceral Pleura
DOI: https://doi.org/10.7759/cureus.81473
[2024] Supplementary Methods from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.32698137
[2024] Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
DOI: https://doi.org/10.1158/2159-8290.cd-23-1217
[2024] Simulation and navigation techniques in VATS and RATS
DOI: https://doi.org/10.21037/vats-24-4
[2024] Prognosis of non‐small cell lung cancer with postoperative regional lymph node recurrence
DOI: https://doi.org/10.1111/1759-7714.15265
[2024] RNF31 promotes proliferation and invasion of hepatocellular carcinoma via nuclear factor kappaB activation
DOI: https://doi.org/10.1038/s41598-023-50594-3
[2023] The oncogenic role of <scp>LGR6</scp> overexpression induced by aberrant Wnt/β‐catenin signaling in lung cancer
DOI: https://doi.org/10.1111/1759-7714.15169
[2023] OA19.05 Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
DOI: https://doi.org/10.1016/j.jtho.2023.09.098
[2023] Anatomy of the lung revisited by 3D-CT imaging
DOI: https://doi.org/10.21037/vats-23-21
[2023] Right middle lobectomy + S3 segmentectomy case.
DOI: https://doi.org/10.21037/asvide.2023.051
[2023] Clinicopathological features and surgical outcomes of lobectomy combined with segmentectomy: a cohort study
DOI: https://doi.org/10.21037/jtd-22-696
[2023] Risk factors for late-onset pulmonary fistula after pulmonary segmentectomy
DOI: https://doi.org/10.21037/jtd-22-1212
[2022] Video-assisted thoracoscopic segmentectomy with combined chest wall resection: A case report
DOI: https://doi.org/10.1186/s13019-022-01996-3
[2022] Identification and molecular analysis of RNF31 Q622H germline polymorphism
DOI: https://doi.org/10.3892/ol.2022.13514
[2022] Vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination: a rare case report
DOI: https://doi.org/10.21037/amj-22-13
[2022] Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma
DOI: https://doi.org/10.1002/mc.23448
[2022] Clinical and anatomical features of the lateral costal artery and vein
DOI: https://doi.org/10.1038/s41598-022-14318-3
[2022] RAB11A Expression Is Associated With Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma
DOI: https://doi.org/10.1245/s10434-022-11833-5
[2022] ASO Visual Abstract: RAB11A Expression is Associated with Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma
DOI: https://doi.org/10.1245/s10434-022-11875-9
[2022] A “Catlike Cry” as a Symptom of Congenital Tracheoesophageal Fistula
DOI: https://doi.org/10.1016/j.chest.2021.11.037
[2022] Complex vs. simple segmentectomy: comparing surgical outcomes in the left upper division
DOI: https://doi.org/10.1007/s11748-022-01816-4
[2021] Surgical outcomes after multiple segmentectomy: a cohort study
DOI: https://doi.org/10.21037/jtd-21-1545
[2021] Multiple segmentectomy case.
DOI: https://doi.org/10.21037/asvide.2021.380
[2021] Taste disorder in a patient with invasive thymoma without myasthenia gravis: a rare case report
DOI: https://doi.org/10.21037/med-21-28
[2021] Lymph node dissection in the right superior mediastinal station during right upper lobectomy.
DOI: https://doi.org/10.21037/asvide.2021.290
[2021] Comprehensive expressional analysis of chemosensitivity‐related markers in large cell neuroendocrine carcinoma of the lung
DOI: https://doi.org/10.1111/1759-7714.14102
[2021] Superior Lingular S4 Segmentectomy
DOI: https://doi.org/10.1016/j.athoracsur.2021.04.050
[2021] Congenital Tracheoesophageal Fistula in an Adult
DOI: https://doi.org/10.1164/rccm.202003-0689im
[2021] A Case of a Malignant Solitary Fibrous Tumor of the Pleura Rapidly Enlarged 17 Years after Its Discovery
DOI: https://doi.org/10.3919/jjsa.82.2149

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（98 件）

科研費（0 件）

所属学会・役職（0 件）